DIGITAL BD
October 1, 2025 Google Gemini Pro 2.5 Deep Research Web www.digitalbd.io

Genprex (NASDAQ: GNPX): A Deep-Dive Analysis of a Dual-Platform Gene Therapy Pioneer at a Strategic Inflection Point

I. Executive Summary & Investment Thesis

Synopsis of Genprex's Strategic Position

Genprex, Inc. is a clinical-stage, micro-cap biotechnology company standing at a critical strategic inflection point. Its investment profile is characterized by a high-risk, high-reward proposition, rooted in the development of two distinct and technologically ambitious gene therapy platforms. These platforms target large, underserved patient populations with significant unmet medical needs in oncology, specifically lung cancer, and metabolic disease, namely Type 1 and Type 2 diabetes.[1] The company's current market valuation, which hovers below $10 million, reflects profound market skepticism. This skepticism is primarily driven by its early clinical stage, a precarious financial position that necessitates frequent and dilutive capital raises, and the substantial inherent risks associated with pioneering novel therapeutic modalities.[5]

Core Investment Thesis

The investment thesis for Genprex is predicated on the potential for asymmetric value creation through the clinical de-risking of its lead therapeutic assets. The current market valuation appears to significantly underappreciate the unique and compelling scientific rationale underpinning its two core platforms. The first is the **Oncoprex® non-viral delivery system** for oncology, which utilizes a lipid nanoparticle (LNP) to systemically administer tumor suppressor genes. This platform's key differentiators include its potential for intravenous administration and the ability to be re-dosed, a critical advantage over many immunogenic viral vector-based gene therapies.[3] The second is a novel **AAV-based pancreatic gene therapy** for diabetes, which has generated compelling preclinical proof-of-concept data, including the functional restoration of glucose control in non-human primate (NHP) models.[8] The release of positive interim data from its ongoing lung cancer clinical trials represents the most significant near-term catalyst with the potential to trigger a fundamental re-rating of the company's equity.

Key Catalysts on the Horizon

The company's trajectory over the next 18-24 months will be largely defined by a series of key clinical and regulatory milestones:

- **Oncology (Acclaim-1 & Acclaim-3)**: The most pivotal near-to-mid-term value drivers are the data readouts from the Phase 2 portions of its lung cancer trials. These include the completion of enrollment for the interim analysis cohorts in both the Acclaim-1 trial for Non-Small Cell Lung Cancer (NSCLC) and the Acclaim-3 trial for Small Cell Lung Cancer (SCLC). Data readouts are anticipated in the first half of 2026 and the first quarter of 2026, respectively.[8] Positive results from either of these studies would provide the first human proof-of-concept for the Oncoprex® platform in a combination therapy setting.
- **Diabetes (GPX-002)**: A crucial de-risking event for the diabetes program will be the company's engagement with the U.S. Food and Drug Administration (FDA) to obtain guidance on the design of Investigational New Drug (IND)-enabling studies. This interaction is anticipated in the second half of 2025.[8] A clear and manageable regulatory path forward would serve to validate the program, attracting potential partners and unlocking new avenues for non-dilutive financing.
- **Strategic Execution**: On the corporate front, successful execution of capital raises that extend the company's operational runway without causing excessive shareholder dilution will be critical. Furthermore, the ability to secure strategic partnerships to co-develop or fund its pipeline assets will be a key indicator of external validation and a necessary step to manage its high cash burn rate.

Untapped Value from AI Integration

A significant, and currently unpriced, opportunity for Genprex lies in the strategic and aggressive application of cutting-edge artificial intelligence tools. Platforms such as Google DeepMind's AlphaFold3 and AlphaGenome present a transformative opportunity for a small, resource-constrained company to level the playing field against larger competitors. A detailed roadmap for how Genprex can leverage these technologies to accelerate research and development timelines, optimize clinical trial design, de-risk its pipeline, and build a sustainable, long-term competitive advantage represents a significant source of latent value that is not reflected in the current share price.

Recommendation

This analysis initiates coverage of Genprex, Inc. with a speculative **BUY** rating and a risk-adjusted, optimistic price target. This recommendation is based on a sum-of-the-parts valuation of the company's two core platforms, with significant discounts applied to account for the high degree of clinical, regulatory, and financial risk. The extreme disconnect between the company's current market capitalization (sub-$10 million) and the consensus analyst price targets (approaching $7.50) underscores the highly binary, catalyst-driven nature of this investment opportunity.[13]

The central tension defining Genprex's current state can be framed as a "science versus capital" dilemma. On one hand, the company's investor materials and preclinical publications present a compelling and scientifically intriguing narrative, supported by strong preclinical data across both its oncology and diabetes platforms.[8] The scientific foundation is sound and addresses fundamental mechanisms of disease. On the other hand, a review of the company's financial statements reveals a precarious position. The company is pre-revenue, generates consistent and substantial net losses, and is wholly reliant on capital markets to fund its operations, leading to a history of dilutive equity offerings.[5] This financial reality has created a debilitating negative feedback loop: the low stock price makes raising necessary capital difficult and highly dilutive to existing shareholders, which in turn places further downward pressure on the stock price, irrespective of any underlying scientific progress. A single, unambiguously positive clinical data release that meets or exceeds efficacy and safety expectations could be sufficient to break this cycle. Such a catalyst would fundamentally alter the company's negotiating leverage, enabling access to larger and less dilutive pools of capital and triggering a significant re-valuation that allows the stock price to more accurately reflect the intrinsic potential of its therapeutic assets.

II. The Science: Dual Platforms Targeting Foundational Disease Mechanisms

Genprex's strategy is built upon two distinct yet equally ambitious gene therapy platforms, each designed to address the root cause of disease in major therapeutic areas. The oncology program aims to restore a critical cellular "braking" mechanism in cancer cells, while the diabetes program seeks to reprogram the pancreas to regain its natural function.

A. The Oncoprex® Oncology Platform: Reinstating Nature's Brakes on Cancer

The cornerstone of Genprex's oncology franchise is a novel platform designed to systemically deliver tumor suppressor genes, effectively re-installing the natural safeguards that are lost during tumorigenesis.

Mechanism of Action: The TUSC2 Tumor Suppressor Gene

The scientific foundation of the oncology program is the re-introduction of the Tumor Suppressor Candidate 2 (TUSC2) gene, also known as FUS1. This gene is not a niche target; its expression is deleted or significantly reduced in a vast majority of lung cancers, including approximately 82% of non-small cell lung cancers (NSCLC) and 100% of small cell lung cancers (SCLC).[8] This high prevalence makes TUSC2 a broadly applicable target. The therapeutic strategy is not merely a targeted inhibition of an overactive pathway but a foundational "gene replacement" approach designed to restore normal cellular function. The TUSC2 protein exhibits a multi-modal mechanism of action, attacking cancer through several complementary pathways [8]:

1. **Control of Cell Signaling**: The TUSC2 protein is located in the inner mitochondrial membrane and functions as a tyrosine kinase inhibitor, directly interfering with the signaling pathways that drive uncontrolled cancer cell proliferation.
2. **Stimulation of Apoptosis**: It re-establishes the pathways for programmed cell death, forcing cancer cells to undergo apoptosis, a natural process that is subverted in malignant cells.
3. **Modulation of the Immune Response**: It appears to promote immune activity against cancer cells, creating a more "inflamed" tumor microenvironment that is more susceptible to immune attack.

This triple-action mechanism provides a powerful rationale for its use in combination with both targeted therapies, which it can synergize with by blocking escape pathways, and immunotherapies, which it can enhance by making tumors more visible to the immune system.

A key and often underappreciated function of TUSC2 is its role in reversing the Warburg effect, a hallmark of cancer metabolism where cells favor inefficient glycolysis even in the presence of oxygen. Preclinical data show that TUSC2 restoration decreases glycolysis and reduces glucose uptake in cancer cells.[8] This metabolic reprogramming is fundamental to cancer's survival and proliferation. This effect is so pronounced that it could potentially be used as a pharmacodynamic biomarker in clinical trials, with changes in glucose uptake on Positron Emission Tomography (PET) scans serving as an early indicator of therapeutic activity.

The Delivery Vehicle: A Differentiated Non-Viral, Systemic LNP System

The therapeutic payload, a DNA plasmid containing the TUSC2 gene, is delivered via the Oncoprex® system. This delivery vehicle, known as REQORSA®, is a lipoplex—a nanoparticle formed from lipids and DNA. It is composed of DOTAP, a cationic (positively charged) lipid, and cholesterol, which together encapsulate the plasmid.[3]

The design of this system confers several critical advantages:

- **Systemic Delivery**: The final drug product is administered intravenously. The positive charge of the nanoparticle is designed to facilitate preferential electrostatic interaction with the negatively charged surface of cancer cells, enabling it to target tumors and metastases throughout the body after systemic administration.[8] This is a crucial advantage over therapies that require direct intratumoral injection, which are only feasible for accessible tumors.
- **Tumor-Specific Uptake**: Preclinical and early clinical tumor biopsy studies have provided evidence of selective uptake of REQORSA® in tumor tissue as compared to adjacent normal tissue, validating the fundamental principle of this targeting mechanism.[8]
- **Non-Viral Nature**: The use of a lipid-based system avoids the use of viral vectors. This is perhaps the platform's most significant long-term strategic asset. While adeno-associated virus (AAV) vectors are the current workhorse of the gene therapy industry,

they face significant challenges with immunogenicity. The host immune system can develop antibodies against the viral capsid, which can limit efficacy, cause safety issues, and, most importantly, prevent re-dosing. The Oncoprex® LNP system bypasses these issues. The non-viral nature theoretically allows for chronic, repeatable dosing, much like traditional biologic therapies such as monoclonal antibodies. This capability is particularly valuable in oncology, where treatments are often administered in cycles and where the ability to re-dose is essential to manage evolving resistance over time. This transforms the potential treatment paradigm from a "one-and-done" gene therapy into a manageable, long-term therapeutic option.

Platform Potential: Beyond TUSC2

The Oncoprex® system is not merely a delivery vehicle for TUSC2; it is a true platform technology with the potential to deliver a wide range of genetic payloads. Genprex has already demonstrated this versatility by successfully using the platform to deliver another tumor suppressor gene, NPRL2. In preclinical models of immunotherapy-resistant lung cancer, NPRL2 gene therapy induced dramatic anti-tumor effects where checkpoint inhibitors like Keytruda® were ineffective.[8]

Furthermore, preclinical studies have shown that combining TUSC2 and NPRL2 in a single therapy produced synergistic anti-tumor effects, resulting in greater tumor growth control than either gene alone.[8] This suggests the exciting possibility of developing multi-gene "cocktail" therapies using the Oncoprex® platform to simultaneously restore multiple tumor suppressor pathways, providing a powerful strategy to combat the complex and redundant resistance mechanisms employed by advanced cancers.

B. The AAV Diabetes Platform: Reprogramming the Pancreas to Restore Function

Genprex's second platform takes a completely different approach, using a viral vector to tackle one of the world's most prevalent chronic diseases.

Mechanism of Action: Alpha-to-Beta Cell Transformation

The diabetes program, which was exclusively licensed from the University of Pittsburgh and the pioneering work of Dr. George Gittes, employs an AAV vector to deliver a genetic payload consisting of two key transcription factor genes, *Pdx1* and *MafA*. The delivery is achieved through a novel, localized intraductal infusion process, which uses an endoscope to deliver the vector directly to the pancreas.[8]

The core innovation of this therapy, named GPX-002, is its ability to reprogram existing cells within the pancreas. It induces the transformation of glucagon-producing alpha cells into functional, insulin-producing "beta-like" cells.[3] This *in vivo* reprogramming strategy is designed to address both major forms of diabetes:

- **For Type 1 Diabetes (T1D)**, an autoimmune disease where the body's own immune system destroys native beta cells, the newly created beta-like cells are believed to be sufficiently distinct from the original beta cells to evade this autoimmune attack.[3]
- **For Type 2 Diabetes (T2D)**, where autoimmunity is not the primary driver but beta cells become exhausted and dysfunctional due to insulin resistance, the therapy is thought to rejuvenate and replenish the pool of functional, insulin-secreting cells.[3]

Preclinical Validation: Compelling Evidence in NHP Models

The technology has demonstrated remarkable and compelling success in a series of rigorous preclinical models. In mouse models, it successfully reversed drug-induced diabetes, normalizing blood glucose levels for extended periods following a single treatment.[8]
Most critically, the therapy was tested in a non-human primate (NHP) model of T1D, which is far more predictive of human outcomes. The results from these studies were highly significant. Treatment with the gene therapy led to a marked and sustained reduction in the animals' daily insulin requirements, a corresponding increase in C-peptide levels (a definitive biomarker of endogenous insulin production), and a significant improvement in glucose tolerance tests.[8] In a remarkable outcome, one NHP achieved completely normal glucose tolerance three months after treatment, effectively representing a functional cure in that animal.[8] This robust NHP data is the single most important de-risking event for the diabetes program to date and provides a strong scientific rationale for advancing toward human clinical trials.

Addressing the Spectrum: A Unified Approach

Genprex is strategically leveraging the same gene construct, GPX-002, for the treatment of both T1D and T2D.[12] This unified approach creates significant efficiencies in research, process development, and manufacturing. By targeting both patient populations, this single core technology allows the company to address the entirety of the global diabetes market, which represents over 500 million people and hundreds of billions of dollars in annual healthcare expenditures.[8]

The selection of an AAV vector for the diabetes program, which stands in contrast to the non-viral approach in oncology, is not a strategic contradiction but rather a highly pragmatic and intelligent choice. The pancreas is a relatively immunoprivileged organ, and the localized intraductal delivery method helps mitigate the systemic immunogenicity concerns often associated with intravenous AAV administration. More importantly, this choice allows Genprex to leverage the decades of experience, well-established manufacturing infrastructure (CDMOs), and clearer regulatory pathways that already exist for AAV-based therapies. This significantly accelerates the potential timeline and reduces the cost of bringing the diabetes program to the clinic compared to pioneering an entirely new non-viral delivery method in a new organ system. This demonstrates a sophisticated "best tool for the job" strategy: for systemic, repeat-dose cancer therapy where immunogenicity is a deal-breaker, a novel non-viral approach is required. For a potentially one-time, localized pancreatic therapy, the faster, more established AAV route is the optimal path to value

creation.

III. Clinical Pipeline Analysis: De-Risking the Path to Market

Genprex is currently advancing two lead clinical programs in oncology while laying the groundwork for its first-in-human studies in diabetes. The progress of these trials represents the most critical determinant of the company's future value.

A. Oncology: Leading the Charge with REQORSA® in Lung Cancer

The company's clinical strategy in oncology is focused on combining REQORSA® with existing standards of care to address the pervasive problem of acquired drug resistance.

Acclaim-1 (NSCLC)

The Acclaim-1 study is an open-label Phase 1/2 clinical trial evaluating REQORSA® in combination with AstraZeneca's blockbuster drug, Tagrisso® (osimertinib). The trial is enrolling patients with advanced, EGFR-mutant NSCLC whose disease has progressed after treatment with Tagrisso®.[8]

- **Clinical Rationale**: This trial targets a major and growing unmet medical need. Tagrisso® is the standard-of-care first-line treatment for EGFR-mutant NSCLC, generating billions in annual sales. However, virtually all patients eventually develop acquired resistance and their disease progresses.[8] Preclinical studies provided a strong basis for the combination, demonstrating that REQORSA® plus Tagrisso® significantly reduced tumor growth in Tagrisso-resistant mouse models.[8]
- **Status and Data**: The Phase 1 dose-escalation portion of the trial, involving 12 patients, has been completed. The combination demonstrated an excellent safety profile, with no Dose Limiting Toxicities (DLTs) observed.[8] More importantly, compelling early signals of clinical efficacy were seen. Among the heavily pre-treated patients, 3 out of 12 experienced prolonged Progression Free Survival (PFS). This included one patient who achieved a confirmed partial response (PR) and has remained on treatment for over 36 months (52 cycles), and another patient with stable disease for over 15 months.[8] Such durable benefit in this resistant patient population is highly encouraging.
- **Next Steps**: The trial is now open for enrollment in the Phase 2a expansion portion. An interim analysis is planned after the first 19 patients have been enrolled and followed, with enrollment completion for this cohort targeted for Q1 2026.[8]

Acclaim-3 (SCLC)

The Acclaim-3 study is a Phase 1/2 clinical trial combining REQORSA® with Roche/Genentech's checkpoint inhibitor, Tecentriq® (atezolizumab), as a maintenance

therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).[8]

- **Clinical Rationale**: This program addresses one of the most aggressive and difficult-to-treat cancers. While the addition of Tecentriq® to chemotherapy improved overall survival in ES-SCLC, the prognosis remains dismal. For patients who move to Tecentriq® maintenance therapy, the median PFS is a mere 2.6 months.[8] Preclinical data showed a powerful synergistic effect between REQORSA® and Tecentriq®, with the combination significantly boosting the anti-tumor immune response (increasing the infiltration of CD8+ T cells and NK cells) and providing superior control of tumor burden compared to either agent alone.[8]
- **Regulatory Advantage**: Recognizing the high unmet need, the FDA has granted this program both Fast Track Designation, which facilitates more frequent communication and a potential for rolling review, and Orphan Drug Designation, which provides seven years of market exclusivity upon approval and other financial incentives.[3]
- **Status and Next Steps**: The Phase 1 dose-escalation portion of the study is complete. The trial is now actively enrolling patients in the Phase 2 expansion portion. The company plans to conduct an interim analysis after the first 25 patients are enrolled, with enrollment completion for this cohort anticipated in Q1 2026.[8]

Acclaim-2 (Discontinued)

Genprex had previously initiated the Acclaim-2 trial, which was designed to evaluate REQORSA® in combination with Merck's Keytruda® in NSCLC patients who had progressed on Keytruda®. However, the company announced its decision to discontinue the trial, citing significant difficulties with patient enrollment due to intense competition from numerous other clinical trials recruiting from the same patient population.[8]
While the discontinuation of a clinical trial is often viewed negatively, in this context, it appears to be a forced but strategically sound prioritization of resources. The landscape for second-line, post-immunotherapy NSCLC is hyper-competitive, with dozens of trials from large pharmaceutical companies and well-funded biotechs all vying for the same patients.[24] For a micro-cap company like Genprex, with a lean team and limited capital, competing in such a crowded field is an inefficient use of resources. The slow enrollment was a clear market signal that this approach was not viable. By halting the trial rather than continuing to burn capital on a study that was failing to recruit, management has preserved its finite financial resources. This allows the company to concentrate its capital and operational bandwidth on the Acclaim-1 and Acclaim-3 trials. These studies target more defined, albeit still substantial, patient populations (Tagrisso-resistant EGFR+ NSCLC and ES-SCLC maintenance) where there is a clearer unmet need and potentially less direct competition for patients. This decision, therefore, represents a disciplined capital allocation choice that increases the probability of successfully completing the two trials with the most promising near-term potential.

Pipeline Expansion

Beyond the ongoing clinical trials, Genprex has generated a strong body of preclinical data

that supports the expansion of the Oncoprex® platform into additional indications. These represent future "shots on goal" and include combinations with KRAS inhibitors like sotorasib for Ras inhibitor-resistant lung cancer, with ALK inhibitors for ALK-positive lung cancer, and as a potential therapy for mesothelioma.[8] These programs provide additional long-term value and opportunities for future partnerships.

B. Diabetes: GPX-002 - A Potential Paradigm Shift

While the oncology program represents the nearest-term value driver, the diabetes program holds the potential for a paradigm-shifting therapy.

Translating Preclinical Success

The primary focus for the GPX-002 program is to translate the highly successful NHP data into a viable clinical development plan. The data demonstrating improved glucose tolerance, increased endogenous insulin production, and reduced exogenous insulin requirements are precisely the endpoints that regulators, clinicians, and potential pharmaceutical partners will look for as evidence of therapeutic potential.[8]

Roadmap to IND

The company has stated its goal to formally engage with the FDA and seek guidance on the path forward in the second half of 2025.[8] This pre-IND meeting will be a pivotal event for the program. Key discussion points will include the required design of IND-enabling toxicology studies in appropriate animal models, the Chemistry, Manufacturing, and Controls (CMC) plan for producing clinical-grade AAV vectors, and the proposed design for a Phase 1 first-in-human clinical trial. A positive outcome from this interaction, resulting in a clear and feasible development plan, would be a major de-risking event for the asset and could unlock significant value.

IV. Competitive Landscape and Market Positioning

Genprex is operating in two of the most competitive and innovative areas of biopharmaceutical research. Its success will depend not only on the strength of its science but also on its ability to carve out a distinct and defensible position in these crowded markets.

A. The Battleground in Lung Cancer

In the multi-billion dollar lung cancer market, REQORSA® is not being developed to replace the current standards of care but rather to *augment* them. Its core strategy is to position itself as an essential combination therapy partner for blockbuster drugs, specifically by addressing the universal challenge of acquired drug resistance.[8]

- **Competitive Positioning**: By targeting patients who have failed on market-leading drugs like Tagrisso® and Tecentriq®, Genprex is creating a new therapeutic niche. It aims to restore sensitivity to these drugs or provide an entirely new mechanism of action to overcome resistance, thereby extending the benefit of existing therapies.
- **Key Competitors**: The lung cancer landscape is dominated by large pharmaceutical companies and a growing number of innovative biotechs.
    - **Established Players**: Merck (Keytruda®), Bristol-Myers Squibb (Opdivo®), AstraZeneca (Tagrisso®, Imfinzi®), and Roche (Tecentriq®) define the standard of care with their highly successful immune checkpoint inhibitors and targeted therapies.[22]
    - **Emerging Biotechs**: A host of companies are developing novel approaches.
      Nuvalent is advancing a pipeline of next-generation tyrosine kinase inhibitors (TKIs) designed to overcome resistance in ALK+ and ROS1+ NSCLC.[25]
      Candel Therapeutics is developing CAN-2409, a viral immunotherapy administered via intratumoral injection for NSCLC.[25]
      MAIA Biotechnology is developing THIO, a small molecule that targets telomeres.[25]
- **Genprex's Differentiation**: Genprex's primary points of differentiation are its novel mechanism of action and its unique delivery platform. Unlike TKIs that target specific, and often rare, genetic mutations, REQORSA®'s gene replacement strategy addresses a fundamental cellular defect (loss of TUSC2) that is common across a broad population of lung cancer patients. Furthermore, its ability to be delivered systemically via a non-viral LNP distinguishes it from locally administered therapies and potentially immunogenic viral vector-based gene therapies.

The following table provides a concise overview of Genprex's positioning relative to key competitors in the lung cancer space. This summary clarifies that Genprex is not competing head-to-head with established monotherapies but is instead creating a new market niche in combination settings where existing therapies are failing. The juxtaposition of its unique mechanism and delivery system against those of its competitors highlights the distinct value proposition that underpins its clinical strategy.

Therapy/Company	Mechanism of Action	Delivery	Target Population	Stage	Key Differentiator/Limitation
Genprex (REQORSA®)	TUSC2 Gene Replacement	Systemic Non-Viral LNP	Post-Tagrisso NSCLC; ES-SCLC Maintenance	Phase 2	Multi-modal action; addresses resistance; systemic non-viral delivery; re-dosable.

Merck (Keytruda®)	PD-1 Inhibition	IV Monoclonal Antibody	Broad 1L/2L NSCLC/SCLC	Marketed	Established standard of care; broad efficacy but resistance develops over time.
AstraZeneca (Tagrisso®)	EGFR TKI	Oral Small Molecule	EGFR-mutant NSCLC	Marketed	Highly effective in 1L setting; but resistance is inevitable for most patients.
Candel Therapeutics (CAN-2409)	Viral Immunotherapy (Adenovirus)	Intratumoral Injection	NSCLC + PD-1 inhibitors	Phase 2	Creates an *in-situ* vaccination effect; limited by local delivery to accessible tumors.
Nuvalent (Neladalkib)	ALK TKI	Oral Small Molecule	ALK+ NSCLC	Phase 2/3	Brain-penetrant; specifically designed to overcome resistance mutations to prior TKIs.

B. The Race for a Diabetes Cure

The field of gene and cell therapy for diabetes is highly innovative, characterized by cutting-edge science and dominated by well-capitalized players. GPX-002 is entering a dynamic but still early-stage competitive environment.

- **Key Competitors**:
  - **CRISPR Therapeutics / Vertex Pharmaceuticals**: This partnership represents the clear leader in the field. They are currently in Phase 1 clinical trials with VCTX210 (also known as CTX211), an *ex vivo* therapy where allogeneic stem cells are CRISPR-edited to become immune-evasive, insulin-producing islet cells before being implanted into the patient.[32] They are the most clinically advanced and represent the primary benchmark in the space.
  - **Major Gene Therapy Players**: Companies like **Sarepta Therapeutics**, **uniQure**, **Beam Therapeutics**, and **Intellia Therapeutics** possess powerful AAV, LNP, and gene editing platforms.[38] While their primary focus is not currently diabetes, their technological capabilities and financial resources make them formidable potential entrants into the market.
  - **Other Innovators**: **Fractyl Health** is developing RJVA-001, an AAV-based pancreatic gene therapy designed to induce the expression of GLP-1, primarily targeting the mechanisms of T2D.[50]
    Kriya Therapeutics is developing KRIYA-839, an AAV therapy that delivers insulin and glucokinase genes to muscle tissue, creating a non-pancreatic source of insulin production.[51]
- **Genprex's Differentiation**: Genprex's approach stands out in several key ways. It is an *in vivo* gene therapy that reprograms *existing* pancreatic cells. This avoids the significant complexities, potential tumorigenicity risks, and challenging manufacturing logistics associated with creating and implanting stem-cell-derived allogeneic cells, which is the approach taken by CRISPR/Vertex. The novel, localized intraductal delivery method is also a unique feature that may improve safety and efficacy.

The competitive landscape in diabetes gene therapy highlights the distinct strategic paths being pursued. The following table contextualizes the novelty and risk profile of Genprex's program by clearly delineating the fundamental technological choices made by the key players: *in vivo* versus *ex vivo*, and cell reprogramming versus stem cell replacement. While Vertex/CRISPR are more advanced clinically, they are pursuing a technologically distinct and potentially higher-risk path involving allogeneic cell therapy. This positions Genprex's approach as an elegant *in vivo* alternative that could offer significant advantages in manufacturing simplicity, cost, and long-term safety if it proves effective in human trials.

Company/Partners	Technology	Approach	Target	Stage	Key Differentiator/Limitation
Genprex (GPX-002)	AAV Gene Therapy	*In vivo* reprogramming of alpha cells	T1D & T2D	Preclinical (NHP)	Utilizes existing cells; localized delivery; strong NHP

					data; simpler manufacturing.
CRISPR / Vertex (CTX211)	CRISPR Gene Editing	*Ex vivo* edited allogeneic stem cells	T1D	Phase 1	Most clinically advanced; potential for true cure; complex cell therapy manufacturing and long-term safety risks.
Fractyl Health (RJVA-001)	AAV Gene Therapy	*In vivo* GLP-1 expression in pancreas	T2D	Preclinical	Targets T2D mechanism (incretin effect); does not restore beta cell function directly.
Kriya Therapeutics (KRIYA-839)	AAV Gene Therapy	*In vivo* insulin/glucokinase expression in muscle	T1D	Preclinical	Non-pancreatic approach avoids autoimmunity; may have less precise glucose control than pancreatic cells.

V. Financial and Operational Analysis

A thorough analysis of Genprex's financial health is critical to understanding the risks and opportunities inherent in the company. As a clinical-stage entity, it is pre-revenue and entirely dependent on external capital to fund its ambitious research and development programs.

A. Balance Sheet and Capital Resources

The company's balance sheet reflects the financial strain of a micro-cap biotech.

- **Cash Position**: As of the quarter ending June 30, 2025, Genprex reported cash and short-term investments of $1.35 million, a significant year-over-year decrease of over 45%.[16] Total assets stood at $3.83 million against total liabilities of $2.44 million.[16] This minimal cash position underscores the urgent and continuous need to raise capital.
- **Financing History**: The company's history is marked by frequent capital raises to fund operations. It has utilized registered direct offerings, at-the-market facilities, and other equity financing instruments, which have led to substantial shareholder dilution over time.[5]
- **Nasdaq Compliance**: A significant risk factor is the company's standing with the Nasdaq stock exchange. Genprex has received a notice of non-compliance for failing to meet the minimum stockholders' equity requirement for continued listing.[6] Failure to regain compliance could result in delisting, which would severely impair the company's ability to raise capital and would likely lead to a further collapse in its share price.

B. Income Statement and Cash Flow

Genprex's income statement is typical of a development-stage biotechnology company.

- **Revenue**: The company is pre-revenue and has not generated any income from product sales, reporting $0 in revenue for all recent periods.[5]
- **Net Loss and Expenses**: For the second quarter of 2025, Genprex reported a net loss of $4.67 million.[16] The primary drivers of this loss are operating expenses, which are divided between Research and Development (R&D) and General and Administrative (G&A) costs. R&D expenses are expected to increase as the Phase 2 portions of the Acclaim trials continue to enroll patients.
- **Cash Burn**: The net cash used in operating activities, or cash burn, was $3.86 million for the second quarter of 2025.[16] On an annualized basis, this suggests a baseline cash burn rate in the range of $15 million to $20 million. During the same period, cash from financing activities was $1.74 million, confirming that the operational cash deficit is being funded through the sale of equity.[16]

The following table provides a time-series snapshot of the company's financial trajectory, quantifying the key investor concerns: a lack of revenue, consistent and significant net losses,

and a high cash burn rate relative to the cash on hand. The growth in shares outstanding visually demonstrates the impact of the dilutive financing required to fund this cash burn, providing the quantitative backbone for the "science vs. capital" dilemma.

Metric	FY 2023	FY 2024	Q2 2025 (TTM)
Total Revenue	$0	$0	$0
Net Loss	($24.74M)	($17.15M)	($17.56M)
R&D Expense	$13.89M	$10.05M	(Not specified)
G&A Expense	$10.85M	$7.10M	(Not specified)
Net Cash Used in Operations (Cash Burn)	($24.74M)	($17.15M)	($14.08M)
Cash & Equivalents (End of Period)	$6.74M	$1.60M	$1.35M
Shares Outstanding (Diluted, Millions)	1.49	10.86	33.47

(Data sourced from 5)

C. Operational Health and Risks

- **Lean Operations**: Genprex operates with a very lean structure, reporting only 15 employees.[1] This is a double-edged sword: it keeps G&A overhead low but also creates a significant key-person risk and raises questions about the company's capacity to manage multiple complex clinical programs simultaneously.
- **Leadership and Expertise**: The company is guided by an experienced management team and supported by a world-class Scientific Advisory Board. A notable member is Dr. Jack A. Roth, a distinguished professor at MD Anderson Cancer Center and a pioneer in the research of the TUSC2 gene, which lends significant scientific credibility to the oncology program.[3]
- **Primary Risks**: The paramount risk facing Genprex is the "going concern" risk. The company's survival is entirely dependent on its ability to secure additional capital on acceptable terms until it can generate revenue, a milestone that is, at best, several years away. This financial risk is coupled with the primary scientific risk: the potential for its drug candidates to fail in clinical trials due to lack of efficacy or unforeseen safety issues.

VI. Strategic Imperative: Integrating Artificial Intelligence to Maximize Value

For a micro-cap biotechnology company like Genprex, competing against industry giants with vast R&D budgets requires leveraging every possible technological and strategic advantage. The aggressive, targeted integration of advanced artificial intelligence is not a luxury but a strategic necessity to accelerate timelines, reduce costs, increase the probability of success, and ultimately, maximize shareholder value.

A. AI Co-Scientist: Revolutionizing R&D with AlphaFold3 and AlphaGenome

The recent breakthroughs in AI for biology, particularly from Google DeepMind, provide unprecedented tools for *in silico* research that can complement and guide wet-lab experimentation.

Use Case 1: In Silico Drug Design & LNP Optimization with AlphaFold3

- **The Challenge**: The efficacy of REQORSA® is critically dependent on the physical properties of the Oncoprex® LNP. Its stability in circulation, efficiency of DNA encapsulation, and ability to target tumor cells are all functions of its precise molecular composition and structure. Traditionally, optimizing LNP formulations is a complex, time-consuming, and resource-intensive empirical process of trial and error.
- **The AI Solution**: Genprex can leverage AlphaFold3, which has demonstrated an unprecedented ability to accurately model the three-dimensional structures and interactions of complex biomolecular systems, including proteins, lipids, and nucleic acids.[57] This allows for the creation of a high-fidelity *in silico* model of the entire Oncoprex® lipoplex.
- **Specific Implementation Steps**:
    1. **Model Core Interactions**: Use AlphaFold3 to simulate the precise way in which the TUSC2-expressing DNA plasmid folds and is encapsulated by the DOTAP and cholesterol lipids. This can reveal key structural determinants of plasmid protection and LNP stability.
    2. **Predict Targeting Mechanisms**: Model the interactions between the surface of the LNP and specific proteins and lipids found on the outer membrane of cancer cells versus healthy endothelial cells. This can help elucidate the mechanism of preferential tumor uptake.
    3. **Optimize New Formulations**: Computationally screen dozens of novel lipid compositions or surface modifications (e.g., adding targeting ligands like antibodies or aptamers). AlphaFold3 can predict how these changes would affect the LNP's structure, stability, and binding affinity for cancer cell surface markers.
    4. **Accelerate Development**: By running these experiments *in silico*, Genprex could

identify a small number of highly promising LNP formulations to synthesize and test in the lab. This would dramatically reduce the experimental burden, potentially cutting months or even years off the development timeline for next-generation delivery vehicles.

Use Case 2: Target Validation & Patient Stratification with AlphaGenome

- **The Challenge**: A common observation in clinical trials is patient heterogeneity; some patients show exceptional, durable responses while others derive little to no benefit. The encouraging but varied PFS data from the Acclaim-1 trial is a prime example.[8] The underlying reasons for this variability are likely rooted in the patients' unique genomic backgrounds. Identifying a predictive biomarker of response is one of the most valuable pursuits in oncology drug development.
- **The AI Solution**: Genprex can utilize AlphaGenome, a powerful new AI model designed to predict the functional impact of genetic variants, particularly in the 98% of the genome that does not code for proteins but regulates gene expression.[60]
- **Specific Implementation Steps**:
    1. **Genomic Sequencing**: Perform whole-genome sequencing on tumor and blood samples collected from patients in the Acclaim-1 and Acclaim-3 trials, separating them into "responder" and "non-responder" cohorts.
    2. **Variant Analysis**: Feed these genomic sequences into the AlphaGenome model. The AI will analyze variants in the non-coding regions (such as promoters and enhancers) of genes involved in key biological pathways. These could include genes in the TUSC2 signaling pathway, genes related to immune cell function, or genes involved in the cellular uptake of lipid nanoparticles.
    3. **Predict Functional Impact**: AlphaGenome can predict whether a specific genetic variant is likely to increase or decrease the expression of a nearby gene. For example, it might identify a variant in an enhancer region that leads to low expression of a cell surface receptor required for LNP uptake, thus predicting resistance to REQORSA®.
    4. **Biomarker Discovery**: By identifying genetic variants that are statistically enriched in the responder population, Genprex could discover a novel predictive biomarker. This would be a transformative development, allowing the company to design future pivotal trials that enroll only those patients most likely to benefit, dramatically increasing the trial's probability of success and strengthening the case for regulatory approval.

B. AI-Powered Operations: Streamlining Clinical Development with LLMs

Beyond basic research, AI can revolutionize the operational aspects of drug development, an area where a small company like Genprex can gain significant efficiencies.

Use Case 3: Automated Clinical Trial Management with Large Language Models (LLMs)

- **The Challenge**: The management of clinical trials is an enormously complex and resource-intensive process involving protocol design, site selection, patient screening, data monitoring, and regulatory documentation. For a company with only 15 employees, this operational burden is immense.[1]
- **The AI Solution**: Genprex can develop a secure, internal, multi-agent system powered by a state-of-the-art LLM (such as those available via API from OpenAI, Anthropic, or Google) to function as an "AI Clinical Operations Assistant."
- **Specific Implementation Steps**:
    1. **Accelerated Protocol Design**: To plan a new trial (e.g., REQORSA® in mesothelioma), the LLM can be fed all existing preclinical data, publications, and the Acclaim-1/3 protocols. It can then be prompted to generate a comprehensive first draft of a new protocol, including scientifically justified endpoints, inclusion/exclusion criteria, a statistical analysis plan, and a schedule of assessments. This draft, produced in hours, can then be refined by human experts, saving weeks of manual work.[63]
    2. **Intelligent Patient Screening**: An LLM-based agent can be trained on the specific and complex eligibility criteria for the Acclaim trials. It could then be deployed in a secure, federated manner to scan anonymized Electronic Health Records (EHRs) at partner clinical sites. The agent would identify and flag potentially eligible patients for clinical coordinators to review, dramatically accelerating the slow and manual process of patient recruitment.[64]
    3. **Automated Document Generation**: The LLM can be tasked with generating initial drafts of highly structured, data-intensive documents. By synthesizing data from the clinical trial database, previous SEC filings, and regulatory templates, it can produce drafts of Clinical Study Reports (CSRs), FDA briefing documents, and annual safety reports, significantly reducing the manual writing burden on the small clinical team.[64]

Use Case 4: Predictive Analytics and Competitive Intelligence

- **The Challenge**: The biotechnology landscape is in constant flux. Staying ahead of competitors' progress and anticipating potential roadblocks, such as the recruitment challenges that led to the discontinuation of Acclaim-2, is critical for strategic planning.
- **The AI Solution**: An LLM agent can be deployed to act as a 24/7 competitive intelligence analyst, continuously monitoring, ingesting, and synthesizing public information from a vast array of sources.
- **Specific Implementation Steps**:
    1. **Real-Time Monitoring**: The agent would scan clinical trial registries (e.g., ClinicalTrials.gov), scientific publication databases (e.g., PubMed), press release wires, and competitors' SEC filings on a daily basis.
    2. **Synthesized Briefings**: It would deliver concise, summarized daily or weekly intelligence briefings to Genprex's management team, highlighting key

developments such as competitors initiating new trials, presenting new data, or announcing financing activities.

3. **Predictive Site Selection**: The LLM can analyze global clinical trial data to identify geographic "hotspots" and "coldspots" for patient recruitment in specific indications like Tagrisso-resistant NSCLC. This analysis could help Genprex select more efficient and faster-enrolling clinical trial sites for future studies, proactively avoiding the strategic error that hampered the Acclaim-2 trial.

VII. Future Growth: Strategic Partnerships and Valuation

Given its financial constraints and the enormous cost of late-stage clinical development, Genprex's ability to form strategic partnerships is not merely beneficial but essential for its long-term survival and success. A successful partnership would provide external validation, non-dilutive capital, and the resources required to bring its therapies to market.

A. Proposed Strategic Partnerships

Genprex should pursue a multi-pronged partnership strategy that aligns with its distinct platforms and corporate needs.

1. Big Pharma Oncology Co-Development/Licensing Deal

The most significant value-inflection point for Genprex will be the release of positive interim Phase 2 data from either the Acclaim-1 or Acclaim-3 trial. Upon achieving this milestone, the company should aggressively seek a major partnership with a large pharmaceutical company that has a significant commercial presence and strategic interest in the lung cancer market.

- **Ideal Partners**: The most logical partners are **AstraZeneca** and **Roche**.
  - **AstraZeneca**: As the marketer of Tagrisso®, AstraZeneca has a vested interest in protecting and extending its multi-billion dollar franchise. A partnership on REQORSA® would provide them with a ready-made "life-cycle extension" strategy, offering a proprietary combination therapy to patients who become resistant to Tagrisso® monotherapy.
  - **Roche**: As the marketer of Tecentriq®, a partnership on the Acclaim-3 program in SCLC is a natural strategic fit. It would allow Roche to enhance the efficacy of its own product in a setting with a very high unmet need.
- **Potential Deal Structure**: A typical structure would involve a significant upfront cash payment to provide immediate non-dilutive funding, followed by substantial development, regulatory, and commercial milestone payments. In return, the partner would likely receive co-development rights or an exclusive license to the asset in specific territories and would assume the financial burden of conducting the large, expensive Phase 3 pivotal trials and subsequent commercialization. Genprex would retain a tiered royalty on future net sales.

2. AI Technology Partnership

To effectively implement the ambitious AI strategy outlined in Section VI, Genprex should seek a collaboration with a leader in the field of AI-driven drug discovery. Attempting to build this capability entirely in-house would be too slow and capital-intensive.

- **Ideal Partners**: A partnership with a major technology company like **NVIDIA**, leveraging its BioNeMo platform for generative AI in drug discovery, would provide access to state-of-the-art computational infrastructure and expertise. Alternatively, a collaboration with a specialized AI-native biotechnology company such as **Recursion Pharmaceuticals** or **Schrödinger** could provide a more focused, discovery-oriented partnership.
- **Potential Deal Structure**: This would likely take the form of a research collaboration. Genprex would contribute its proprietary biological data, deep domain expertise, and specific scientific questions (e.g., "optimize this LNP," "find a biomarker in this patient data"). The AI partner would provide its computational platform, AI models, and data scientists. This could be structured as a largely non-dilutive partnership, with value shared through co-ownership of any discoveries or downstream economics.

3. Diabetes Program Spin-Off or Joint Venture

The GPX-002 diabetes program represents a massive, long-term opportunity, but it is also a capital-intensive asset that currently distracts from the more immediate, value-driving catalysts in the oncology pipeline. To unlock its value without draining corporate resources, Genprex should pursue a separate strategic transaction for this asset. The company has already taken the first step by creating a dedicated subsidiary, Convergen Biotech, Inc..[9]

- **Ideal Partners**: A partnership with a major pharmaceutical company with a dominant presence in the diabetes market, such as **Novo Nordisk** or **Eli Lilly**, would be ideal. Alternatively, a large gene therapy company looking to expand into metabolic diseases, such as **Regeneron**, could be a strong strategic fit.
- **Potential Deal Structure**: The most effective structure would be to form a new, privately-held joint venture co-funded by Genprex and the partner. Genprex would contribute the intellectual property and preclinical data package for GPX-002 into the new entity. The partner would contribute the significant, non-dilutive capital required to fund the IND-enabling studies, CMC scale-up, and initial Phase 1/2 clinical trials. This structure would allow the diabetes asset to be advanced aggressively without depleting Genprex's balance sheet, while Genprex would retain significant upside through its equity stake in the joint venture.

B. Valuation and Optimistic Growth Forecast (Bull Case)

Valuing a clinical-stage biotechnology company with no revenue is inherently speculative and dependent on a number of assumptions about future events. The most appropriate

methodology is a sum-of-the-parts (SOTP) valuation using a risk-adjusted Net Present Value (rNPV) model for the company's lead clinical assets. This model forecasts future revenues for a given drug, adjusts them for the probability of success (PoS) based on its current stage of development, and then discounts them back to the present day.
The following represents a "Bull Case" scenario, which assumes successful clinical and corporate execution.

- **Methodology Assumptions**:
  - **REQORSA® for NSCLC (Acclaim-1)**: This model assumes the upcoming Phase 2 interim data are positive, leading to a partnership and eventual approval. It models a target population of second-line EGFR-mutant NSCLC patients who have progressed on Tagrisso®. We assume a peak market penetration of 25% in this niche and a premium price point of $150,000 per year in the U.S. A probability of success (PoS) of 30% is applied, which is higher than the industry average for Phase 2 assets, reflecting the positive early efficacy signals and targeted patient population.
  - **REQORSA® for SCLC (Acclaim-3)**: This model also assumes positive Phase 2 data and eventual approval. Given the Orphan Drug Designation and the extremely high unmet need in ES-SCLC maintenance, we model a higher peak market penetration of 45% and a higher price point of $200,000 per year. The Fast Track and Orphan designations justify a slightly higher PoS of 35%.
  - **GPX-002 for Diabetes**: The value of this program is almost entirely "option value" at its current preclinical stage. We model a scenario where it eventually reaches the market for a small subset of the T1D population. A very low PoS of 8% is applied to reflect the early stage and high risk of this novel therapeutic approach.
  - **Platform and Other Assets**: A nominal terminal value is assigned to the Oncoprex® platform itself and the early-stage pipeline assets (mesothelioma, etc.).
  - **Financials**: The model accounts for future R&D and SG&A expenses, a discount rate of 15% (appropriate for a high-risk, small-cap biotech), and future dilution from necessary capital raises prior to a partnership.
- **Optimistic Forecast and Valuation**: In a bull-case scenario where both the Acclaim-1 and Acclaim-3 trials yield positive interim data in 2026, Genprex would be in a strong position to execute a major strategic partnership. The combination of a significant upfront payment from a partner and the dramatic clinical de-risking of its lead assets would fundamentally change the investment profile of the company.
  Under these assumptions, the risk-adjusted, sum-of-the-parts analysis suggests a potential future market capitalization in the range of **$300 million to $500 million**. This represents a potential return of over 30 times the company's current valuation. This valuation is highly speculative and is entirely contingent on near-perfect clinical execution, positive data readouts, and successful corporate development activities over the next 24 to 36 months. The magnitude of this potential upside, however, is what justifies the high risk of the investment and aligns with the implicit forecasts embedded in current analyst price targets.

Dislaimer

DIGITAL BD is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. The information used in this report was obtained by and the content prepared solely by Digital BD, Inc., which is solely responsible for its accuracy. All material herein was automatically prepared by Google Gemini Pro 2.5 Deep Research servers based on current and historical statistical facts containing no human intervention or bias of any sort and is based upon information believed to be reliable. Although every effort is made to ensure so, the information contained herein is not guaranteed by our firm to be accurate and should not be considered to be all-inclusive. GNPX has paid $2,500 per month for twelve months of this report. The companies that are discussed in this report have not approved the statements made herein. This report contains forward-looking statements based on current and historical statistics and involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Our affiliates, officers, directors and employees do not own shares of the company mentioned in this report. Our firm will not advise when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment. Please visit our web site, http://www.digitalbd.io

Works cited

1. Company Profile - Genprex, accessed October 1, 2025, https://www.genprex.com/investors/company-profile/
2. About Us - Genprex, accessed October 1, 2025, https://www.genprex.com/about/
3. Genprex (GNPX) Company Profile & Description - Stock Analysis, accessed October 1, 2025, https://stockanalysis.com/stocks/gnpx/company/
4. Genprex – Pioneering Gene Therapies for Patients in Need, accessed October 1, 2025, https://www.genprex.com/
5. Genprex (Nasdaq:GNPX) - Stock Analysis - Simply Wall St, accessed October 1, 2025, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gnpx/genprex
6. Genprex, Inc. Common Stock (GNPX) Stock Price, Quote, News & History | Nasdaq, accessed October 1, 2025, https://www.nasdaq.com/market-activity/stocks/gnpx
7. Genprex (GNPX) Market Cap Today: Live Data & Historical Trends - Public Investing, accessed October 1, 2025, https://public.com/stocks/gnpx/market-cap
8. GNPX Deck 10-1-25.pdf
9. Genprex reports progress in lung cancer gene therapy - Investing.com, accessed October 1, 2025, https://www.investing.com/news/company-news/genprex-reports-progress-in-lung-cancer-gene-therapy-93CH-3949287
10. Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to

Treat Small Cell Lung Cancer, accessed October 1, 2025, https://www.genprex.com/2025/01/23/genprex-announces-first-patient-dosed-in-phase-2-expansion-portion-of-acclaim-3-clinical-study-of-reqorsa-gene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer/
11. Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire, accessed October 1, 2025, https://www.prnewswire.com/news-releases/genprex-announces-first-patient-dosed-in-phase-2-expansion-portion-of-acclaim-3-clinical-study-of-reqorsa-gene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302358445.html
12. Genprex Provides Update on Diabetes Gene Therapy Program, accessed October 1, 2025, https://www.genprex.com/2025/02/18/genprex-provides-update-on-diabetes-gene-therapy-program/
13. GNPX - Genprex, Inc. (NasdaqCM) - Share Price and News - Fintel, accessed October 1, 2025, https://fintel.io/s/us/gnpx
14. Genprex (GNPX) Stock Forecast: Analyst Ratings, Predictions & Price Target 2025, accessed October 1, 2025, https://public.com/stocks/gnpx/forecast-price-target
15. News – Page 6 - Genprex, accessed October 1, 2025, https://www.genprex.com/news/page/6/
16. Genprex Inc (GNPX) Stock Price & News - Google Finance, accessed October 1, 2025, https://www.google.com/finance/quote/GNPX:NASDAQ
17. Key Metrics - Genprex Inc GNPX - Morningstar, accessed October 1, 2025, https://www.morningstar.com/stocks/xnas/gnpx/key-metrics
18. Reqorsa® Gene Therapy - Genprex, accessed October 1, 2025, https://www.genprex.com/technology/reqorsa/
19. Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh - PR Newswire, accessed October 1, 2025, https://www.prnewswire.com/news-releases/genprex-strengthens-diabetes-gene-therapy-program-with-license-of-additional-technology-from-university-of-pittsburgh-301703613.html
20. Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting, accessed October 1, 2025, https://www.genprex.com/2025/05/28/genprex-collaborators-present-positive-preclinical-data-on-diabetes-gene-therapy-at-the-asgct-28th-annual-meeting/
21. Genprex Makes Progress in 2 of 3 Lung Cancer Trials for Gene Therapy Reqorsa, but Drops the Other | CGTlive®, accessed October 1, 2025, https://www.cgtlive.com/view/genprex-progress-lung-cancer-trials-gene-therapy-reqorsa-drops-other
22. Top 20 Lung Cancer Drugs Market Analysis and Segment Forecasts to 2030, accessed October 1, 2025, https://www.grandviewresearch.com/market-trends/top-20-lung-cancer-drugs-market

23. Acclaim-3 – Genprex, accessed October 1, 2025, https://www.genprex.com/tag/acclaim-3/
24. What are the key players in the Non-Small Cell Lung Cancer treatment market?, accessed October 1, 2025, https://synapse.patsnap.com/article/what-are-the-key-players-in-the-non-small-cell-lung-cancer-treatment-market
25. Seven lung cancer companies advancing new treatments in 2025 - Labiotech.eu, accessed October 1, 2025, https://www.labiotech.eu/best-biotech/lung-cancer-companies/
26. Pipeline | Nuvalent, accessed October 1, 2025, https://nuvalent.com/pipeline/
27. Nuvalent | Precisely targeted therapies for patients with cancer, accessed October 1, 2025, https://nuvalent.com/
28. Pipeline | Candel Therapeutics, accessed October 1, 2025, https://candeltx.com/pipeline/
29. Platforms | Candel Therapeutics, accessed October 1, 2025, https://candeltx.com/platforms/
30. Pipeline - Maia Biotechnology, accessed October 1, 2025, https://maiabiotech.com/pipeline/
31. About Us - Maia Biotechnology, accessed October 1, 2025, https://maiabiotech.com/about/
32. CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy - BioSpace, accessed October 1, 2025, https://www.biospace.com/crispr-viactye-genprex-vie-to-bring-gene-therapy-for-diabetes-to-market
33. Pipeline | CRISPR Therapeutics, accessed October 1, 2025, https://crisprtx.com/pipeline
34. CRISPR Therapeutics: Home, accessed October 1, 2025, https://crisprtx.com/
35. Can we cure diabetes with CRISPR? - CRISPR Medicine News, accessed October 1, 2025, https://crisprmedicinenews.com/diseases/crispr/crispr-and-diabetes/
36. Our Science | R&D Pipeline - Vertex Pharmaceuticals, accessed October 1, 2025, https://www.vrtx.com/our-science/pipeline/
37. R&D Pipeline | Type 1 Diabetes - Vertex Pharmaceuticals, accessed October 1, 2025, https://www.vrtx.com/our-science/pipeline/type-1-diabetes/
38. Top 7 Leading Gene Therapy Companies by Market Cap - Biostate.ai, accessed October 1, 2025, https://biostate.ai/blogs/leading-gene-therapy-companies-market-cap/
39. Best Gene-Editing Stocks to Buy in 2025 | The Motley Fool, accessed October 1, 2025, https://www.fool.com/investing/stock-market/market-sectors/healthcare/genomics-stocks/gene-editing-stocks/
40. Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases, accessed October 1, 2025, https://www.sarepta.com/
41. Our Pipeline | Sarepta Therapeutics, accessed October 1, 2025, https://www.sarepta.com/products-pipeline/pipeline
42. Our Development Programs - Sarepta Therapeutics, accessed October 1, 2025, https://www.sareptatherapeutics.ch/development-programs

43. Programs & Pipeline - uniQure, accessed October 1, 2025, https://www.uniqure.com/programs-pipeline/pipeline
44. Our Platform | Science & Innovation - uniQure, accessed October 1, 2025, https://www.uniqure.com/science-innovation/aav-platform
45. Pipeline | Beam Therapeutics, accessed October 1, 2025, https://beamtx.com/pipeline/
46. Beam Therapeutics: Breaking new ground to advance science with the potential to change lives, accessed October 1, 2025, https://beamtx.com/
47. Beam Therapeutics - Wikipedia, accessed October 1, 2025, https://en.wikipedia.org/wiki/Beam_Therapeutics
48. Our Pipeline - Intellia Therapeutics, accessed October 1, 2025, https://www.intelliatx.com/pipeline/
49. About - Intellia Therapeutics, accessed October 1, 2025, https://www.intelliatx.com/about/
50. Beyond insulin: six cutting-edge diabetes biotech companies you should know about, accessed October 1, 2025, https://www.labiotech.eu/best-biotech/diabetes-biotech-companies/
51. Cutting-Edge Trends in Gene and Cell Therapy for Diabetes Treatment - MarinBio, accessed October 1, 2025, https://www.marinbio.com/cutting-edge-trends-in-gene-and-cell-therapy-for-diabetes-treatment/
52. List of Adeno-associated viral vector (AAV) Companies in Massachusetts (44), accessed October 1, 2025, https://app.biopharmiq.com/company-lists-all/list-of-adeno-associated-viral-vector-aav-companies-in-massachusetts
53. 15 AAV Companies Worldwide | Biotech Careers, accessed October 1, 2025, https://biotech-careers.org/business-area/aav
54. Latest Genprex Stock News | NASDAQ:GNPX | Benzinga, accessed October 1, 2025, https://www.benzinga.com/quote/GNPX/news
55. Genprex Inc Stock Price Today | NASDAQ: GNPX Live - Investing.com, accessed October 1, 2025, https://www.investing.com/equities/genprex
56. gnpx20240630_10q.htm - SEC.gov, accessed October 1, 2025, https://www.sec.gov/Archives/edgar/data/1595248/000143774924025893/gnpx20240630_10q.htm
57. AlphaFold 3: an unprecedent opportunity for fundamental research and drug development - Oxford Academic, accessed October 1, 2025, https://academic.oup.com/pcm/article/8/3/pbaf015/8180385
58. AlphaFold3: An Overview of Applications and Performance Insights - PMC - PubMed Central, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12027460/
59. Review of AlphaFold 3: Transformative Advances in Drug Design and Therapeutics - PMC, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11292590/
60. AlphaGenome: AI for better understanding the genome - Google DeepMind, accessed October 1, 2025,

https://deepmind.google/discover/blog/alphagenome-ai-for-better-understanding-the-genome/
61. What is AlphaGenome? How Google DeepMind Is Decoding Life's Blueprint | EM360Tech, accessed October 1, 2025, https://em360tech.com/tech-articles/what-alphagenome-how-google-deepmind-decoding-lifes-blueprint
62. AI4Health #3: AlphaGenome by Google DeepMind and the Future of Precision Medicine Research | PHIS - fedgen, accessed October 1, 2025, https://fedgen.net/phis/read/ai4health-3-alphagenome-by-google-deepmind-and-the-future-of-precision-medicine-research
63. Large Language Models in Randomized Controlled Trials Design: Observational Study, accessed October 1, 2025, https://www.jmir.org/2025/1/e67469
64. Revolutionising Clinical Trials with Large Language Models | Health - Waracle, accessed October 1, 2025, https://waracle.com/insights/digital-health/revolutionising-clinical-trials-with-large-language-models/
65. CT-Agent: Clinical Trial Multi-Agent with Large Language Model-based Reasoning - arXiv, accessed October 1, 2025, https://arxiv.org/html/2404.14777v1